Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy-Reference-Cited by-同舟云学术

Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy

Published:2015-10-14 Issue:6 Volume:102 Page:654-661
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Miyakawa Yoshitaka,Katsutani Shinya,Yano Takahiro,Nomura Shosaku,Nishiwaki Kaichi,Tomiyama Yoshiaki,Higashihara Masaaki,Shirasugi Yukari,Nishikawa Masakatsu,Ozaki Katsutoshi,Abe Takayuki,Kikuchi Kayoko,Kanakura Yuzuru,Fujimura Kingo,Ikeda Yasuo,Okamoto Shinichiro

Funder

Japan Medical Association, Center for Clinical Trials

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-015-1887-9.pdf

Reference23 articles.

1. Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329–35.

2. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549–54.

3. Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Ikeda Y, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicate chronic ITP cases in Japan. Int J Hematol. 2005;81:162–8.